Innate Pharma (IPH) Q3 2026 TU earnings summary

Executive summary

• Portfolio priorities include partnered lacutamab, wholly owned IPH4502, and AstraZeneca-partnered monalizumab, with clinical milestones approaching through H1 2027.

• Cash and financial assets of €96.8 million at September 30, 2026, support an anticipated cash horizon through the end of Q1 2028.

Financial highlights

• Nine-month revenue was €3.4 million, versus €2.3 million in 9M 2025, mainly from AstraZeneca and Sanofi collaboration and licensing agreements.

• Cash, cash equivalents and financial assets totaled €96.8 million; financial liabilities were €16.2 million at September 30, 2026.

• The cash balance included the $75 million Sobi upfront payment and gross proceeds from an August 2026 €30 million private placement.

Outlook and guidance

• TELLOMAK-3 first patient dosing is expected in Q1 2027; an FDA accelerated approval filing for lacutamab in Sézary syndrome is planned for H2 2027, once the confirmatory study is underway.

• PACIFIC-9 high-level Phase 3 data are expected in H1 2027, revised from H2 2026 due to the event-driven study design.

• IPH4502 Phase 1 dose-escalation data are scheduled for presentation at ENA on November 18, 2026; dose-escalation enrollment is complete.

• Anticipated cash horizon extends through the end of Q1 2028.